Houston, Texas, November 18, 2014 – Metanome, Inc. today announced the appointment of F. John Mills, MD, PhD to the company’s Board of Directors. Dr. Mills is an accomplished healthcare industry executive and entrepreneur with a background in general management of contract research organizations and pharmaceutical development spanning 30 years. Dr. Joseph Petrosino, founder of Metanome, said, “We welcome the opportunity to benefit from Dr. Mills’ pharmaceutical and biotechnology services expertise, as well as his proven entrepreneurial acumen and track record of growing revenues, profitability and market share.”
Dr. Mills is Chairman of BioStorage Technologies Inc., a company he co-founded in 2003 to provide management, logistics, and storage services for biological specimens and data to life science companies. Prior to forming BioStorage Technologies, Dr. Mills held various senior executive level positions at Covance Inc. including Global President of Central Laboratory Services and previously Senior Vice President of European Clinical Research Services. Before Covance, he was Medical Director of Janssen Pharmaceutical Ltd UK and then moved to Singapore as Janssen Pharmaceutica’s Regional Medical Director for SE Asia.
Dr. Mills said that he is excited about the opportunity to help lead Metanome to the next level in its development. “Metanome is quickly making a name for itself by partnering with innovative pharmaceutical companies and providing best in class metagenomic services and data analytics, all fueled by access to the breadth and depth of microbiome research at Baylor College of Medicine.”
Mills received his M.D. from Cambridge University and his Ph.D. in endocrinology from Surrey University in the United Kingdom. He holds diplomas in pharmaceutical medicine, aviation medicine, and marketing and has authored more than 40 scientific papers as well as a textbook on aviation medicine. He currently sits on the boards of directors for Intelsius plc, HC1.com Corporation and previously served on the boards for IBT Laboratories and ChanTest Inc. that was recently acquired by Charles River Labs.
About Metanome™, Inc.
Metanome provides comprehensive metagenomic services and data analysis focused on solutions that benefit human health and improve environmental conditions and industrial processes worldwide. The company is a BCM Technologies, Inc. portfolio company. Building on the research conducted at the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine, Metanome has extensive experience with highly diverse microbiome sample types. For more information, please visit www.metanome.com.